Fuso Pharmaceutical Industries,Ltd. (JP:4538)
:4538
Top Page
Fuso Pharmaceutical Industries,Ltd.
(4538)
Select Model
Select Model
Rating:60Neutral
Price Target:
¥2,432.00
▲(5.05% Upside)
Action:ReiteratedDate:10/29/25
Fuso Pharmaceutical Industries' overall stock score is driven by solid financial performance in terms of revenue growth and profitability, but is hampered by significant cash flow challenges. Technical indicators suggest neutral momentum, while valuation is mixed with a negative P/E ratio but a strong dividend yield.
Positive Factors
Prudent leverage & strong equity base
A debt-to-equity of 0.54 and ~49.5% equity ratio indicate prudent leverage and a solid capital base. This balance-sheet strength supports funding for R&D, manufacturing upkeep, and working capital without forcing frequent external financing, improving resilience to industry cycles.
Negative Factors
Negative free cash flow
Sustained negative free cash flow and a deficient operating cash flow to net income ratio indicate the company is not converting reported profits into cash. This strains capacity to self-fund capex, dividends, or M&A, raising dependence on external financing or asset monetization over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Prudent leverage & strong equity base
A debt-to-equity of 0.54 and ~49.5% equity ratio indicate prudent leverage and a solid capital base. This balance-sheet strength supports funding for R&D, manufacturing upkeep, and working capital without forcing frequent external financing, improving resilience to industry cycles.
Read all positive factors
Fuso Pharmaceutical Industries,Ltd. (4538) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥20.32B
Dividend Yield3.71%
Average Volume (3M)17.49K
Price to Earnings (P/E)5.8
Beta (1Y)0.62
Revenue Growth7.50%
EPS Growth-281.41%
CountryJP
Employees1,370
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)99.84
Shares Outstanding9,451,169
10 Day Avg. Volume18,340
30 Day Avg. Volume17,486
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.63
Price to Sales (P/S)0.34
P/FCF Ratio-3.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Fuso Pharmaceutical Industries,Ltd. Business Overview & Revenue Model
Company Description
Fuso Pharmaceutical Industries,Ltd. manufactures and sells pharmaceutical products in Japan. The company offers ethical drugs, such as injectables and artificial kidney dialysates; and medical machinery and equipment. It also rents real estate pro...
How the Company Makes Money
Fuso Pharmaceutical Industries, Ltd. primarily makes money by selling pharmaceutical products (mainly prescription/hospital-use drugs and related medical products) in Japan through distribution channels serving hospitals, clinics, and pharmacies. ...
Fuso Pharmaceutical Industries,Ltd. Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
74
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.50B | 60.56B | 55.41B | 51.02B | 49.63B | 49.25B |
| Gross Profit | 4.08B | 16.19B | 13.52B | 13.36B | 12.91B | 13.62B |
| EBITDA | 1.24B | 5.96B | 3.69B | 4.47B | 4.30B | 4.60B |
| Net Income | 462.00M | -3.29B | 1.38B | 1.60B | 1.48B | 1.61B |
Balance Sheet | ||||||
| Total Assets | 86.99B | 82.52B | 76.46B | 72.81B | 69.66B | 70.23B |
| Cash, Cash Equivalents and Short-Term Investments | 3.16B | 6.26B | 5.12B | 8.01B | 7.35B | 7.07B |
| Total Debt | 28.23B | 21.29B | 12.72B | 11.41B | 12.09B | 13.20B |
| Total Liabilities | 53.81B | 49.48B | 39.79B | 37.15B | 35.12B | 36.54B |
| Stockholders Equity | 33.18B | 33.04B | 36.66B | 35.65B | 34.53B | 33.68B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -5.43B | -2.62B | 1.32B | 2.20B | 2.09B |
| Operating Cash Flow | 0.00 | -3.31B | 627.00M | 2.87B | 3.61B | 3.27B |
| Investing Cash Flow | 0.00 | -3.17B | -3.54B | -1.39B | -1.66B | -1.02B |
| Financing Cash Flow | 0.00 | 7.62B | 14.00M | -813.00M | -1.67B | -2.45B |
Fuso Pharmaceutical Industries,Ltd. Technical Analysis
Neutral
2315.00
Price Trends
2349.76
Negative
2285.46
Positive
2186.06
Positive
Market Momentum
-6.75
Positive
43.09
Neutral
10.22
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4538, the sentiment is Neutral. The current price of 2315 is below the 20-day moving average (MA) of 2364.00, below the 50-day MA of 2349.76, and above the 200-day MA of 2186.06, indicating a neutral trend. The MACD of -6.75 indicates Positive momentum. The RSI at 43.09 is Neutral, neither overbought nor oversold. The STOCH value of 10.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4538.
Fuso Pharmaceutical Industries,Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥14.87B | 16.22 | ― | ― | -5.41% | ― | |
64 Neutral | ¥6.20B | 11.64 | ― | 3.21% | 4.25% | ― | |
62 Neutral | ¥9.06B | 15.24 | ― | 2.55% | 3.23% | 42.87% | |
60 Neutral | ¥20.32B | 5.79 | ― | 3.71% | 7.50% | -281.41% | |
52 Neutral | ¥20.05B | 72.72 | ― | 3.65% | 9.53% | -155.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥11.70B | 7.11 | ― | 1.06% | 5.42% | -62.03% |
* Healthcare Sector Average
JP:4538
Fuso Pharmaceutical Industries,Ltd.
2,296.00
183.09
8.67%
JP:2929
Pharma Foods International Co., Ltd.
692.00
-94.35
-12.00%
JP:4512
Wakamoto Pharmaceutical Co., Ltd.
337.00
18.68
5.87%
JP:4524
Morishita Jintan Co., Ltd.
2,220.00
218.42
10.91%
JP:4539
Nippon Chemiphar Co., Ltd.
1,718.00
280.87
19.54%
JP:4574
Taiko Pharmaceutical Co., Ltd.
297.00
33.00
12.50%
Fuso Pharmaceutical Industries,Ltd. Corporate Events
Fuso Pharmaceutical Secures ¥13.4 Billion Syndicated Loan to Expand Dialysis Production
Mar 31, 2026
Fuso Pharmaceutical Industries has signed a ¥13.4 billion syndicated commitment-type term loan arranged by Sumitomo Mitsui Banking Corporation to finance its key manufacturing expansion plan. The funds will support construction of a second fo...
Fuso Pharmaceutical Profit Slumps Despite Modest Sales Growth
Feb 17, 2026
Fuso Pharmaceutical Industries reported non-consolidated net sales of ¥48.27 billion for the nine months ended December 31, 2025, up 3.4% year on year, but operating profit dropped 34.8% to ¥2.37 billion and ordinary profit fell 33.7%, w...
Fuso Pharmaceutical Sees Profit Slide Despite Higher Sales, Keeps Dividend Outlook Firm
Feb 12, 2026
Fuso Pharmaceutical Industries reported non-consolidated net sales of ¥48.27 billion for the nine months ended December 31, 2025, up 3.4% year on year, while operating profit fell 34.8% and profit dropped 29.9%, signaling margin pressure desp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.